Skip to content

Brain-Computer Interface based on Cortical Electrodes

Brain-Computer Interface based on Cortical Electrodes - BCI with ECoG

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON39771
Enrollment
48
Registered
2007-10-30
Start date
2007-11-16
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

n.a.

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: epilepsy patients with implanted electrodes for diagnostic purposes age 12 years and older (no upper limit) no metal objects in or around the body (braces, pacemaker, metal fragments) ;(Amendement september 2012): a vagal nerve stimulator is permitted

Exclusion criteria

Exclusion criteria: x

Design outcomes

Primary

MeasureTime frame
The results are expected to lead up to the development of a first implantable prototype for paralyzed patients. The key questions that will be addressed are: 1) which features of brainsignals obtained from cortical surface electrodes can be used for BCI, 2) which brain areas produce the best results for BCI cursor control, 3) can subjects use multiple brain-areas to control a cursor in multiple directions 4) can target areas be pre-localized accurately with fMRI (amendment 12 jan 2012:) 5) are the signals obtained with a prototype implantable amplifier adequate for BCI. (amendement september 2012): 2) which brain areas produce the best results for BCI control, 3) can target areas be pre-localized accurately with fMRI, 4) are the signals obtained with a prototype implantable amplifier adequate for BCI.

Secondary

MeasureTime frame
(amendment 12 jan 2012) A prototype implantable EEG amplifier will be tested outside the body in three patients. The outcome measure is quality of the EEG signal (signal-to-noise ratio) and actual BCI performance with that signal, as compared to those measure obtained with the clinical EEG system (measurements are performed in parallel) (amendment september 2012) A prototype implantable EEG amplifier will be tested outside the body. The outcome measure is quality of the EEG signal (signal-to-noise ratio) and actual BCI performance with that signal, as compared to those measure obtained with the clinical EEG system (measurements are performed in parallel). In addition, we would like to determine the optimal settings of the device for accurate BCI control.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)